CR20180029A - POTENTIAL INHIBITORS OF THE INTERLEUCINE RECEIVER 23 AND ITS USE TO TREAT INFLAMMATORY DISEASES - Google Patents
POTENTIAL INHIBITORS OF THE INTERLEUCINE RECEIVER 23 AND ITS USE TO TREAT INFLAMMATORY DISEASESInfo
- Publication number
- CR20180029A CR20180029A CR20180029A CR20180029A CR20180029A CR 20180029 A CR20180029 A CR 20180029A CR 20180029 A CR20180029 A CR 20180029A CR 20180029 A CR20180029 A CR 20180029A CR 20180029 A CR20180029 A CR 20180029A
- Authority
- CR
- Costa Rica
- Prior art keywords
- interleucine
- receiver
- inflammatory diseases
- treat inflammatory
- potential inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona inhibidores peptídicos novedosos del receptor de interleucina 23 y composiciones y métodos relacionados para utilizar estos inhibidores peptídicos para el tratamiento o la prevención de diversas enfermedades y trastornos, incluidas enfermedades intestinales inflamatoriasThe present invention provides novel peptide inhibitors of interleukin 23 and related compositions and methods for using these peptide inhibitors for the treatment or prevention of various diseases and disorders, including inflammatory bowel diseases.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/800,627 US9624268B2 (en) | 2014-07-17 | 2015-07-15 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| PCT/US2015/040658 WO2016011208A1 (en) | 2014-07-17 | 2015-07-15 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| US201562264820P | 2015-12-08 | 2015-12-08 | |
| US201662281123P | 2016-01-20 | 2016-01-20 | |
| PCT/US2016/042680 WO2017011820A2 (en) | 2015-07-15 | 2016-07-15 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20180029A true CR20180029A (en) | 2018-06-05 |
Family
ID=57757647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20180029A CR20180029A (en) | 2015-07-15 | 2016-07-15 | POTENTIAL INHIBITORS OF THE INTERLEUCINE RECEIVER 23 AND ITS USE TO TREAT INFLAMMATORY DISEASES |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP3341011A4 (en) |
| JP (1) | JP6858174B2 (en) |
| KR (1) | KR102513978B1 (en) |
| CN (1) | CN108348580B (en) |
| AU (1) | AU2016293619B2 (en) |
| BR (1) | BR112018000691A2 (en) |
| CA (1) | CA2991984A1 (en) |
| CL (3) | CL2018000128A1 (en) |
| CO (1) | CO2018000349A2 (en) |
| CR (1) | CR20180029A (en) |
| DO (1) | DOP2018000010A (en) |
| EA (1) | EA035733B9 (en) |
| EC (1) | ECSP18002929A (en) |
| HK (2) | HK1257747A1 (en) |
| IL (1) | IL256827A (en) |
| MX (1) | MX2018000542A (en) |
| NI (1) | NI201800008A (en) |
| PE (1) | PE20180571A1 (en) |
| PH (1) | PH12018500086A1 (en) |
| SG (1) | SG10201912066SA (en) |
| SV (1) | SV2018005614A (en) |
| UA (1) | UA123772C2 (en) |
| WO (1) | WO2017011820A2 (en) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME02651B (en) | 2012-06-13 | 2017-06-20 | Incyte Holdings Corp | Substituted tricyclic compounds as fgfr inhibitors |
| LT2968443T (en) | 2013-03-15 | 2021-12-10 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| CA2909207C (en) | 2013-04-19 | 2021-11-02 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP3960754A3 (en) | 2014-05-16 | 2022-07-06 | Protagonist Therapeutics, Inc. | Alpha4beta7 integrin thioether peptide antagonists |
| RU2736637C9 (en) | 2014-07-17 | 2021-02-08 | Протагонист Терепьютикс, Инк. | Peptidic interleukin-23 receptor inhibitors for oral administration and use thereof for treating inflammatory intestinal diseases |
| US10301371B2 (en) | 2014-10-01 | 2019-05-28 | Protagonist Therapeutics, Inc. | Cyclic monomer and dimer peptides having integrin antagonist activity |
| EP3200812B8 (en) | 2014-10-01 | 2021-04-28 | Protagonist Therapeutics, Inc. | Novel alpha4beta7 peptide monomer and dimer antagonists |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (en) | 2015-02-20 | 2017-12-26 | Incyte Corp | BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS |
| CR20170390A (en) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | BICYCLE HETEROCICLES AS FGFR INHIBITORS |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| US10407468B2 (en) | 2016-03-23 | 2019-09-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing α4β7 peptide antagonists |
| JP2020505352A (en) * | 2017-01-18 | 2020-02-20 | プロタゴニスト セラピューティクス， インコーポレイテッド | Peptide inhibitors of the interleukin-23 receptor and their use for treating inflammatory diseases |
| AR111960A1 (en) | 2017-05-26 | 2019-09-04 | Incyte Corp | CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION |
| GB2563875B (en) * | 2017-06-28 | 2020-08-19 | Sutura Therapeutics Ltd | Improvements in drug delivery |
| TW201920234A (en) | 2017-09-11 | 2019-06-01 | 美商領導醫療有限公司 | Opioid agonist peptides and uses thereof |
| CA3089868A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| BR112020022373A2 (en) | 2018-05-04 | 2021-02-02 | Incyte Corporation | salts of a fgfr inhibitor |
| TW202019948A (en) * | 2018-07-12 | 2020-06-01 | 美商領導醫療有限公司 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| CN110015978B (en) * | 2019-04-29 | 2021-03-19 | 康化（上海）新药研发有限公司 | Synthesis method of O- [2- [ [ (tert-butyloxycarbonyl) amino ] ethyl ] -N- [ fluorenylmethoxycarbonyl ] -L-tyrosine |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP3997105A4 (en) * | 2019-07-10 | 2023-09-13 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| JOP20220083A1 (en) | 2019-10-14 | 2023-01-30 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP3819307A1 (en) * | 2019-11-07 | 2021-05-12 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
| BR112022010664A2 (en) | 2019-12-04 | 2022-08-16 | Incyte Corp | DERIVATIVES OF A FGFR INHIBITOR |
| JP2023505258A (en) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Tricyclic heterocycles as FGFR inhibitors |
| CN115279782A (en) | 2020-01-15 | 2022-11-01 | 詹森生物科技公司 | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021146441A1 (en) * | 2020-01-15 | 2021-07-22 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US11939361B2 (en) * | 2020-11-20 | 2024-03-26 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of Interleukin-23 receptor |
| TW202313611A (en) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | Tricyclic heterocycles as fgfr inhibitors |
| WO2023288017A2 (en) * | 2021-07-14 | 2023-01-19 | Janssen Biotech, Inc. | Bicyclic peptide inhibitors of interleukin-23 receptor |
| TW202332682A (en) | 2021-12-01 | 2023-08-16 | 丹麥商西蘭製藥公司 | Peptide inhibitors of interleukin-23 receptor |
| WO2023172648A2 (en) * | 2022-03-09 | 2023-09-14 | Glympse Bio, Inc. | Fluorogenic substrates for aminopeptidase detection in biofluids |
| CN114751962B (en) * | 2022-03-17 | 2023-11-07 | 北京大学 | Staple peptide, preparation method and pharmaceutical application thereof |
| WO2024003313A1 (en) | 2022-06-30 | 2024-01-04 | Sanofi | New peptides as selective il-23 receptor antagonists |
| US20240218014A1 (en) * | 2022-11-21 | 2024-07-04 | Janssen Pharmaceutica Nv | Synthesis of a cyclic peptide |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5942492A (en) * | 1996-11-12 | 1999-08-24 | Angstrom Pharmaceuticals, Inc. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
| CN101790538B (en) | 2007-02-15 | 2014-07-30 | 印第安纳大学研究与科技公司 | Ucagon/glp-1 receptor co-agonists |
| CN101990547A (en) * | 2007-07-06 | 2011-03-23 | 瓦勒瑞萨欣Hsj有限合伙公司 | Il-23 receptor antagonists and uses thereof |
| CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
| US9523073B2 (en) | 2010-03-31 | 2016-12-20 | Medical Diagnostic Laboratories, Llc | Elisa for a naturally-occurring soluble truncated form of IL-23 receptor |
| US8946150B2 (en) * | 2011-06-14 | 2015-02-03 | Medical Diagnostic Laboratories, LLC. | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| US9169292B2 (en) * | 2011-06-14 | 2015-10-27 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| EP3065757A4 (en) * | 2013-10-09 | 2017-08-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
| RU2736637C9 (en) * | 2014-07-17 | 2021-02-08 | Протагонист Терепьютикс, Инк. | Peptidic interleukin-23 receptor inhibitors for oral administration and use thereof for treating inflammatory intestinal diseases |
-
2016
- 2016-07-15 CN CN201680049562.2A patent/CN108348580B/en active Active
- 2016-07-15 JP JP2018501178A patent/JP6858174B2/en active Active
- 2016-07-15 UA UAA201801482A patent/UA123772C2/en unknown
- 2016-07-15 WO PCT/US2016/042680 patent/WO2017011820A2/en active Application Filing
- 2016-07-15 AU AU2016293619A patent/AU2016293619B2/en active Active
- 2016-07-15 PE PE2018000053A patent/PE20180571A1/en unknown
- 2016-07-15 BR BR112018000691A patent/BR112018000691A2/en active Search and Examination
- 2016-07-15 EP EP16825301.1A patent/EP3341011A4/en active Pending
- 2016-07-15 SG SG10201912066SA patent/SG10201912066SA/en unknown
- 2016-07-15 CR CR20180029A patent/CR20180029A/en unknown
- 2016-07-15 CA CA2991984A patent/CA2991984A1/en active Pending
- 2016-07-15 EA EA201890325A patent/EA035733B9/en not_active IP Right Cessation
- 2016-07-15 MX MX2018000542A patent/MX2018000542A/en unknown
- 2016-07-15 KR KR1020187004612A patent/KR102513978B1/en active IP Right Grant
-
2018
- 2018-01-09 PH PH12018500086A patent/PH12018500086A1/en unknown
- 2018-01-10 DO DO2018000010A patent/DOP2018000010A/en unknown
- 2018-01-10 IL IL256827A patent/IL256827A/en unknown
- 2018-01-11 NI NI201800008A patent/NI201800008A/en unknown
- 2018-01-15 CO CONC2018/0000349A patent/CO2018000349A2/en unknown
- 2018-01-15 EC ECIEPI20182929A patent/ECSP18002929A/en unknown
- 2018-01-15 SV SV2018005614A patent/SV2018005614A/en unknown
- 2018-01-15 CL CL2018000128A patent/CL2018000128A1/en unknown
- 2018-11-22 CL CL2018003322A patent/CL2018003322A1/en unknown
-
2019
- 2019-01-04 HK HK19100122.0A patent/HK1257747A1/en unknown
- 2019-01-23 HK HK19101174.5A patent/HK1259149A1/en unknown
-
2021
- 2021-02-09 CL CL2021000343A patent/CL2021000343A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2018000010A (en) | PEPTIDE INHIBITORS OF THE INTERLEUCINE RECEIVER 23 AND ITS USE TO TREAT INFLAMMATORY DISEASES | |
| AR119389A1 (en) | INTERLEUKIN-23 RECEPTOR PEPTIDE INHIBITORS AND THEIR USE TO TREAT INFLAMMATORY DISEASES | |
| EA201891199A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| EA201890048A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| EA201890047A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| EA201891202A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| EA201891201A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| GT201600233A (en) | COMPOUNDS AND COMPOSITIONS AS AGENTS OF THE TOLL TYPE 7 RECEIVER | |
| EA201890050A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| EA201890049A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| EA201890051A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| EA201792047A1 (en) | NEW CONNECTIONS | |
| EA201790273A1 (en) | FLAGELLIN COMPOSITIONS AND THEIR APPLICATION | |
| UY37018A (en) | PAD4 BICYCLIC INHIBITORS | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| EA201692529A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISORDERS USING FOLLYSTATINE POLYPEPTIDES | |
| BR112022000328A2 (en) | Interleukin-23 receptor peptide inhibitors and their use to treat inflammatory diseases | |
| UA123202C2 (en) | Antibodies to tau and uses thereof | |
| EA201792604A1 (en) | AUTOTAXIN INHIBITORS AND THEIR APPLICATIONS | |
| MX2020006365A (en) | Quinazolinones as parp14 inhibitors. | |
| EA201692091A1 (en) | CHINOXALINE COMPOUNDS AND THEIR APPLICATION | |
| UY37017A (en) | AZA-BENCIMIDAZOL INHIBITORS OF PAD4 | |
| EA201692313A1 (en) | Derivatives of indolysine as inhibitors of phosphosinositide-3-kinase | |
| BR112017008045A2 (en) | compounds as nik inhibitors | |
| EA201791937A1 (en) | ANTI-INFLAMMATORY POLYPEPTIDES |